Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNB1353 in Healthy Volunteers
NCT05462132Phase 1Completed
- Sponsor
- Synlogic
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Genetically Modified Bacteria, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of synb1353 in homocystinuria (HCU) (8 cohorts), sponsored by Synlogic. Primary endpoint: Number of participants with abnormal laboratory values and/or adverse events. Started Jul 2022; status: completed.
02
Drugs
synb1353
03
Conditions
homocystinuria (HCU)
Beyond the preview
Go deeper on NCT05462132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462132.